Chronic dDAVP infusion in rats decreases the expression of P2Y2 receptor in inner medulla and P2Y2 receptor-mediated PGE2 release by IMCD

Am J Physiol Renal Physiol. 2005 Oct;289(4):F768-76. doi: 10.1152/ajprenal.00177.2005. Epub 2005 May 24.

Abstract

Activation of P2Y2 receptor (P2Y2-R) in inner medullary collecting duct (IMCD) of rat decreases AVP-induced water flow and releases PGE(2). We observed that dehydration of rats decreases the expression of P2Y2 receptor in inner medulla (IM) and P2Y2-R-mediated PGE(2) release by IMCD. Because circulating vasopressin (AVP) levels are increased in dehydrated condition, we examined whether chronic infusion of desmopressin (dDAVP) has a similar effect on the expression and activity of P2Y2-R. Groups of rats were infused with saline or dDAVP (5 or 20 ng/h sc, 5 or 6 days) via osmotic minipumps and euthanized. Urine volume, osmolality, and PGE(2) metabolite content were determined. AQP2- and P2Y2- and V2-R mRNA and/or protein in IM were quantified by real-time RT-PCR and immunoblotting, respectively. P2Y2-R-mediated PGE(2) release by freshly prepared IMCD was assayed using ATPgammaS as a ligand. Chronic dDAVP infusion resulted in low-output of concentrated urine and significantly increased the AQP2 protein abundance in IM. On the contrary, dDAVP infusion at 5 or 20 ng/h significantly decreased P2Y2-R protein abundance (approximately 40% of saline-treated group). In parallel, the relative expression of P2Y2-R vs. AQP2- or V2-R mRNA was significantly decreased. Furthermore, the P2Y2-R-mediated PGE(2) release by IMCD was significantly decreased in rats infused 20 ng/h but not 5 ng/h of dDAVP. Urinary PGE(2) metabolite excretion, however, did not change with dDAVP infusion. In conclusion, chronic dDAVP infusion decreases the expression and activity of P2Y2-R in IM. This may be due to a direct effect of dDAVP or dDAVP-induced increase in medullary tonicity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine Triphosphate / analogs & derivatives
  • Adenosine Triphosphate / pharmacology
  • Animals
  • Aquaporin 2
  • Aquaporins / metabolism
  • Blotting, Western
  • DNA Primers
  • DNA, Complementary / biosynthesis
  • Deamino Arginine Vasopressin / administration & dosage
  • Deamino Arginine Vasopressin / pharmacology*
  • Dinoprostone / metabolism*
  • Infusions, Intravenous
  • Kidney Medulla / drug effects
  • Kidney Medulla / metabolism*
  • Kidney Tubules, Collecting / cytology
  • Kidney Tubules, Collecting / drug effects
  • Kidney Tubules, Collecting / metabolism*
  • Male
  • Purinergic P2 Receptor Antagonists*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Purinergic P2 / biosynthesis*
  • Receptors, Purinergic P2 / metabolism
  • Receptors, Purinergic P2Y2
  • Renal Agents / administration & dosage
  • Renal Agents / pharmacology*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Urodynamics / drug effects

Substances

  • Aqp2 protein, rat
  • Aquaporin 2
  • Aquaporins
  • DNA Primers
  • DNA, Complementary
  • P2ry2 protein, rat
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2Y2
  • Renal Agents
  • adenosine 5'-O-(3-thiotriphosphate)
  • Adenosine Triphosphate
  • Deamino Arginine Vasopressin
  • Dinoprostone